Genelux Investor Presentation Deck

Selective Replication In Tumors Unleashes Immune System Against Cancer Key Takeaways Olvi-Vec is a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body ● ● Kills cancer cells directly Enhances (neo) antigen presentation and stimulates a tumor- specific immune response Converts tumor microenvironment from immunosuppressive (cold state) to immunoreactive (hot state) GENELUX ● ● Olvi-Vec viral infection Oncolysis and release of tumor (neo)antigens 'Cold' tumor before Olvi-Vec No or relatively low number of immune effector cells Relatively high number of immune suppressor cells ● Innate Immune Activation Increase Type I IFNs Increase DAMPS / PAMPS ● Adaptive Immune Activation APCS present (neo)antigens T-cell activation & cytotoxicity Anti-tumor immune memory 'Hot' tumor following Olvi-Vec immunotherapy Increase of proinflammatory cytokines/chemokines Influx of CD8+ effector T cells M2 to M1 transition of tumor-associated macrophages Decrease of immune suppression Changes of tumor gene expression profile Immunogenic tumor cell death Reverse platinum-resistance and synergy with other therapies Vascular collapse PAMPS - Pathogen-associated Molecular Patterns DAMPS-Damage-associated Molecular Patterns 6

View entire presentation